Association of Mild Anemia with Cognitive, Functional, Mood and Quality of Life Outcomes in the Elderly: The “Health and Anemia” Study


Asociacion de anemia leve con calidad de vida en ancianos. Estudio “Health and Anemia”.

Texto en PDF

Ugo Lucca1*, Mauro Tettamanti1, Paola Mosconi2, Giovanni Apolone3, Francesca Gandini1, Alessandro Nobili1, Maria Vittoria Tallone4, Paolo Detoma4, Adriano Giacomin5, Mario Clerico6, Patrizia Tempia6, Adriano Guala7, Gilberto Fasolo8, Emma Riva1

1 Laboratory of Geriatric Neuropsychiatry, Istituto di Ricerche Farmacologiche “Mario Negri”, Milano, Italy2 Laboratory for Medical Research & Consumer Involvement, Istituto di Ricerche Farmacologiche “Mario Negri”, Milano, Italy3 Laboratory of Translational and Outcome Research in Oncology, Istituto di Ricerche Farmacologiche “Mario Negri”, Milano, Italy4 Laboratory of Analysis, Ospedale degli Infermi, Biella, Italy5 County Cancer Registry, Local Health Authority, ASL12, Biella, Italy6 Department of Oncology, Ospedale degli Infermi, Biella, Italy7 Department of Medicine & Geriatrics, Ospedale degli Infermi, Biella, Italy8 Community Medicine, Local Health Authority, ASL12, Biella, Italy

Abstract

Background

In the elderly persons, hemoglobin concentrations slightly below the lower limit of normal are common, but scant evidence is available on their relationship with significant health indicators. The objective of the present study was to cross-sectionally investigate the association of mild grade anemia with cognitive, functional, mood, and quality of life (QoL) variables in community-dwelling elderly persons.

Methods

Among the 4,068 eligible individuals aged 65–84 years, all persons with mild anemia (n = 170) and a randomly selected sample of non-anemic controls (n = 547) were included in the study. Anemia was defined according to World Health Organization (WHO) criteria and mild grade anemia was defined as a hemoglobin concentration between 10.0 and 11.9 g/dL in women and between 10.0 and 12.9 g/dL in men. Cognition and functional status were assessed using measures of selective attention, episodic memory, cognitive flexibility and instrumental and basic activities of daily living. Mood and QoL were evaluated by means of the Geriatric Depression Scale-10, the Short-Form health survey (SF-12), and the Functional Assessment of Cancer Therapy-Anemia.

Results

In univariate analyses, mild anemic elderly persons had significantly worse results on almost all cognitive, functional, mood, and QoL measures. In multivariable logistic regressions, after adjustment for a large number of demographic and clinical confounders, mild anemia remained significantly associated with measures of selective attention and disease-specific QoL (all fully adjusted p<.046). When the lower limit of normal hemoglobin concentration according to WHO criteria was raised to define anemia (+0.2 g/dL), differences between mild anemic and non anemic elderly persons tended to increase on almost every variable.

Conclusions

Cross-sectionally, mild grade anemia was independently associated with worse selective attention performance and disease-specific QoL ratings.

Introduction

Mean blood concentrations of hemoglobin progressively decline with aging [1]. In the elderly persons, hemoglobin concentrations slightly below the lower limit of normal are common and are usually viewed by the physician as having no clinical significance or as a chronic disease marker with no independent effect on health. In recent years however, anemia has been increasingly shown to be associated with a number of health indicators. Fatigue and weakness are common consequences of anemia. Several cross-sectional studies in the elderly persons have reported the association of anemia with functional disability and poorer physical performance [2], decreased muscular strength [3], fall injury events at home [4], and increased frailty risk [5]. Two longitudinal studies suggested that elderly persons with anemia are at increased risk of physical decline and recurrent falls [6], [7]. Anemia can thus have a relevant effect on healthcare needs and, with the increasing rate of growth of the elderly population, become a significant healthcare burden [8], [9].

The hypoxic condition caused by anemia may not only negatively affect physical function but also the cognitive performance, mood, and quality of life (QoL) of the elderly person. Very few studies in community-dwelling elderly persons have explored the relationship of anemia with cognitive performance or mood, and none with QoL. Moreover, those few studies did not exclude moderate to severe anemic individuals from the analyses whose scores likely affected the results.

The main aim of the study was to investigate the association of mild grade anemia with significant health-related variables such as cognitive performance, functional status, mood, and QoL in a sample of community-dwelling elderly persons.

Cambio en la formula del Yectafer


Las inyecciones de hierro Yectafer, utilizadas habitualmente en el tratamiento de las anemias, cambiaron su formulación, modificando uno de los componentes, según anunciaron las autoridades del laboratorio que las produce.

Según señalaron en una conferencia de prensa los responsables en la Argentina del laboratorio AstraZeneca, a partir de ahora el producto estará basado en el hierro “dextrano de bajo peso molecular” –utilizado en Europa, Estados Unidos, Canadá, Israel, Japón y Australia, entre otras regiones-, dejando de lado el hierro denominado “sorbitex”……..leer noticia completa

Comentario: hace dos años haciamos referencia a las muertes por este medicamento presuntamente adulterado, las objeciones que haciamos por entonces en resumen eran las siguientes:

– No existen pruebas que el tratamiento de la anemia en embarazadas mejore la morbimortalidad neonatal. La anemia en la embarazada es basicamente dilucional y no se soluciona con hierro, al menos en una mujer que cursa su embarazo normalmente.

– La inyeccion intramuscular es cuestionable, no solo por el dolor, sino porque deja marcas como tatuajes, y existe riesgo de sarcomas. Si bien el riesgo es bajo, la relacion riesgo-beneficio es alta si se tiene en cuenta que este ultimo no esta comprobado.

– Existen pruebas documentadas, aun en libros, de insuficiencia hepatica severa, por la aplicacion de hierro intramuscular, las muertes ocurridas en aquel momento se debieron a ello. Basta leer simplemente el libro de Goodman y Gilman donde lo dice claramente, y la formulacion que se estaba aplicando no estaba aprobada ni siquiera en los EEUU.

– Astra Zeneca en su momento, junto con el ANMAT adujo problemas de adulteracion de la partida, un fiscal dijo que el hierro encontrado era mayor que el normal con lo que nos encontrariamos ante un problema de calidad. En definitiva…..el fallo fue a favor de la empresa.

– En una carta publicada en aquel viejo blog, al que se le dio el derecho a replica, la directora medica aducia la seguridad del medicamento, que llevaba 27 años en el mercado. Si es asi, entonces porque cambiar ahora?

Demasiadas dudas, demasiadas preguntas, demasiado silencio y demasiado olvido, y demasiadas muertes que pudieran haber sido evitadas. No existe indicacion alguna para hierro en embarazadas.